---
title: "Obefazimod (ABX464) in Ulcerative colitis: References"
description: "Reference list for the formulary evidence report on Obefazimod (ABX464) in Ulcerative colitis. 173 cited documents."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: References

<a id="references"></a>

## 5 References

1. [Abivax ABX464-101 protocol (2018)](https://cdn.clinicaltrials.gov/large-docs/59/NCT03093259/Prot_000.pdf)
2. [Abivax ABX464-101 statistical analysis plan (2018)](https://cdn.clinicaltrials.gov/large-docs/59/NCT03093259/SAP_001.pdf)
3. [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)
4. [Abivax ABX464-102 statistical analysis plan (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/SAP_001.pdf)
5. [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)
6. [Abivax ABX464-103 statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/SAP_001.pdf)
7. [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf)
8. [Abivax ABX464-104 statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/SAP_001.pdf)
9. [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)
10. [Abivax ABX464-105 statistical analysis plan (2025)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/SAP_001.pdf)
11. [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)
12. [Abivax ABX464-106 statistical analysis plan (2025)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/SAP_001.pdf)
13. [Abivax ABX464-902 protocol and statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/14/NCT05121714/Prot_SAP_000.pdf)
14. [Abivax corporate presentation (2026)](https://ir.abivax.com/static-files/ecf996c4-f156-4dac-8e1e-5c4e7cfb8e7d)
15. [Abivax first half 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-business-updates-and-first-half-2026-financial)
16. [Abivax first quarter 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-quarter-2026-financial-results-and-reports)
17. [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)
18. [Abivax full year 2025 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-full-year-2025-financial-results-and-provides)
19. [Abivax obefazimod web page](https://www.abivax.com/our-science/obefazimod/)
20. [Abivax press release, 2026 corporate outlook (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-2026-corporate-outlook)
21. [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week)
22. [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)
23. [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial)
24. [Abivax press release, ABX464-102 authorization (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-initiate-long-term-extension-study-abx464-patients)
25. [Abivax press release, commercial leadership appointments (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-strengthens-commercial-capabilities-strategic-leadership)
26. [Abivax press release, DDW 2026 presentations (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-present-data-obefazimod-digestive-disease-weekr)
27. [Abivax press release, ECCO 2026 presentations (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-evidence-anti-fibrotic-activity-obefazimod)
28. [Abivax press release, patient-reported outcomes from ABTECT induction (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-patient-reported-outcomes-data-phase-3-abtect)
29. [Abivax press release, phase 2a 12-month maintenance data (2019)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-impressive-12-month-efficacy-and-safety-data)
30. [Abivax press release, phase 2a Gastroenterology publication (2021)](https://ir.abivax.com/news-releases/news-release-details/abivax-publishes-data-abx464-induction-and-long-term-maintenance)
31. [Abivax press release, phase 2a induction results (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-impressive-results-clinical-phase-2a-trial-abx464)
32. [Abivax press release, phase 2a six-month maintenance data (2019)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-impressive-new-phase-2a-abx464-ulcerative)
33. [Abivax press release, phase 2a three-year maintenance data (2021)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-update-abx464-clinical-data-and-development)
34. [Abivax press release, phase 2a two-year maintenance data (2020)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-long-lasting-two-year-efficacy-and-safety-data)
35. [Abivax press release, pre-NDA interaction with the FDA (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-pre-nda-interaction-fda-obefazimod)
36. [Abivax press release, UEG late-breaking AT-IR subgroup data (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-late-breaking-presentation-8-week-abtect)
37. [Abivax press release, UEG late-breaking safety data (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-late-breaking-presentation-8-week-abtect-trial)
38. [Abivax press release, UEG Week 2026 presentations (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-present-data-obefazimod-united-european-gastroenterology)
39. [Abivax prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000119312526290817/d111359d424b5.htm)
40. [Adamina et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/6/jjag072/8722674)
41. [Ahuja et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13456955/)
42. [Ananthakrishnan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12148344/)
43. [Apolit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10132720/)
44. [Armuzzi et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6975026/)
45. [Baert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.098/8432840)
46. [Barberio et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33721557/)
47. [Barberio et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12151545/)
48. [Bewtra et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3755276/)
49. [Bloudek et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10390993/)
50. [Butler and Segal (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7619135/)
51. [California Department of Health Care Access and Information Prescription Drug Wholesale Acquisition Cost Increases (2025)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22Manufacturer%20Name%22%2C%22NDC%20Number%22%2C%22Drug%20Product%20Description%22%2C%22WAC%20Effective%20Date%22%2C%22WAC%20Increase%20Amount%22%2C%22WAC%20After%20Increase%22%20FROM%20%2246b78eef-5952-4fff-84c7-1fa758990ce8%22%20WHERE%20%22Drug%20Product%20Description%22%20LIKE%20%27RINVOQ%25%27%20OR%20%22Drug%20Product%20Description%22%20LIKE%20%27ZEPOSIA%25%27)
52. [California Department of Health Care Access and Information Prescription Drug Wholesale Acquisition Cost Increases (2026)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22manufacturer_name%22%2C%22ndc%22%2C%22drug_prod_desc%22%2C%22wac_effective_date%22%2C%22wac_increase_amount%22%2C%22wac_after_increase%22%20FROM%20%22dda8a083-bc81-4f6d-b02f-935a2df70328%22%20WHERE%20%22drug_prod_desc%22%20LIKE%20%27SKYRIZI%25%27%20OR%20%22drug_prod_desc%22%20LIKE%20%27Xeljanz%25%27%20OR%20%22drug_prod_desc%22%20LIKE%20%27Entyvio%25%27)
53. [California Department of Health Care Access and Information Prescription Drugs Introduced to Market (2023)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22Manufacturer%20Name%22%2C%22NDC%20Number%22%2C%22Drug%20Product%20Description%22%2C%22Date%20Introduced%20to%20Market%22%2C%22WAC%20at%20Introduction%22%20FROM%20%22f0899438-0fb5-42d5-87f5-621e2f0b1b51%22%20WHERE%20%22Drug%20Product%20Description%22%20LIKE%20%27VELSIPITY%25%27%20OR%20%22Drug%20Product%20Description%22%20LIKE%20%27OMVOH%25%27)
54. [Chebli et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5501810/)
55. [Cichewicz et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130125/)
56. [ClinicalTrials.gov NCT02731885](https://clinicaltrials.gov/study/NCT02731885)
57. [ClinicalTrials.gov NCT02792686](https://clinicaltrials.gov/study/NCT02792686)
58. [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259)
59. [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results)
60. [ClinicalTrials.gov NCT03368118](https://clinicaltrials.gov/study/NCT03368118)
61. [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)
62. [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003)
63. [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)
64. [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396)
65. [ClinicalTrials.gov NCT04023396 results](https://clinicaltrials.gov/study/NCT04023396?tab=results)
66. [ClinicalTrials.gov NCT05032560](https://clinicaltrials.gov/study/NCT05032560)
67. [ClinicalTrials.gov NCT05121714](https://clinicaltrials.gov/study/NCT05121714)
68. [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)
69. [ClinicalTrials.gov NCT05177835](https://clinicaltrials.gov/study/NCT05177835)
70. [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203)
71. [ClinicalTrials.gov NCT05507203 results](https://clinicaltrials.gov/study/NCT05507203?tab=results)
72. [ClinicalTrials.gov NCT05507216](https://clinicaltrials.gov/study/NCT05507216)
73. [ClinicalTrials.gov NCT05507216 results](https://clinicaltrials.gov/study/NCT05507216?tab=results)
74. [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)
75. [ClinicalTrials.gov NCT06456593](https://clinicaltrials.gov/study/NCT06456593)
76. [ClinicalTrials.gov NCT07453784](https://clinicaltrials.gov/study/NCT07453784)
77. [CMS fact sheet, negotiated prices for initial price applicability year 2026 (2024)](https://cms.gov/files/document/fact-sheet-negotiated-prices-initial-price-applicability-year-2026.pdf)
78. [CMS fact sheet, third cycle of negotiation (2026)](https://www.cms.gov/files/document/fact-sheet-medicare-drug-price-negotiation-third-cycle.pdf)
79. [CMS MIPS Quality ID 275 specification (2025)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_275_MIPSCQM.pdf)
80. [CTIS.eu 2022-500537-84-01](https://ctis.eu/trial/2022-500537-84-01)
81. [CTIS.eu 2023-505297-15-00](https://ctis.eu/trial/2023-505297-15-00)
82. [CTIS.eu 2023-505299-31-00](https://ctis.eu/trial/2023-505299-31-00)
83. [CTIS.eu 2023-509226-21-00](https://ctis.eu/trial/2023-509226-21-00)
84. [CTIS.eu 2024-514561-20-00](https://ctis.eu/trial/2024-514561-20-00)
85. [D'Haens et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.138/8432748)
86. [Dadoo et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13312674/)
87. [Danese et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/OP260-ABTECT-ATIR-19OCT2026-Danese-UEGW2026.pdf)
88. [Digestive Disease Week poster, ABTECT integrated safety (2026)](https://www.abivax.com/wp-content/uploads/2026/04/abivax-poster-iss-sands-ddw-2026.pdf)
89. [Dignass et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11550281/)
90. [Ding et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9802455/)
91. [Dubinsky et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8528151/)
92. [Dulai et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/abivax-poster-favorable-safety-acg-2026.pdf)
93. [EMA paediatric investigation plan decision P/0205/2024 (2024)](https://www.ema.europa.eu/en/documents/pip-decision/p-0205-2024-ema-decision-14-june-2024-acceptance-modification-agreed-paediatric-investigation-plan-obefazimod-emea-003196-pip01-22-m01_en.pdf)
94. [EMA paediatric investigation plan decision, March 2025 (2025)](https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000189672-ema-decision-20-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-obefazimod_en.pdf)
95. [Entyvio prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125476s66lbl.pdf)
96. [EU Clinical Trials Information System 2022-500535-36-01](https://euclinicaltrials.eu/ctis-public/view/2022-500535-36-01)
97. [EU Clinical Trials Information System 2022-500536-11-01](https://euclinicaltrials.eu/ctis-public/view/2022-500536-11-01)
98. [EU Clinical Trials Information System 2023-505297-15-00](https://euclinicaltrials.eu/ctis-public/view/2023-505297-15-00)
99. [EU Clinical Trials Information System 2023-505299-31-00](https://euclinicaltrials.eu/ctis-public/view/2023-505299-31-00)
100. [EU Clinical Trials Information System 2023-509226-21-00](https://euclinicaltrials.eu/ctis-public/view/2023-509226-21-00)
101. [EU Clinical Trials Information System 2024-514561-20-00](https://euclinicaltrials.eu/ctis-public/view/2024-514561-20-00)
102. [FDA draft guidance, ulcerative colitis drug development (2022)](https://www.fda.gov/media/158016/download)
103. [Fumery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658168/)
104. [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)
105. [Gros and Kaplan (2023)](https://pubmed.ncbi.nlm.nih.gov/37698559/)
106. [Gulati et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40351121/)
107. [Health Research Authority research summary, ABX464 drug-drug interaction study](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-2-part-drug-drug-interaction-study-of-abx464-in-healthy-volunteers)
108. [Heeren et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.097/8432669)
109. [Holubar et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2791910/)
110. [Honap et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42322247/)
111. [Hracs et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12158780/)
112. [Humira prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125057s425lbl.pdf)
113. [ICER special assessment of Entyvio to inform CMS negotiation (2026)](https://icer.org/wp-content/uploads/2026/03/Entyvio_Final-Evidence-Report_For-Publication_030326.pdf)
114. [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)
115. [Imuran prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/016324s040lbl.pdf)
116. [Jess et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17156150/)
117. [Katsoula et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41284688/)
118. [Kilic et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37042969/)
119. [Kobayashi et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32913180/)
120. [Lanzotti et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42251531/)
121. [Le Berre et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37573077/)
122. [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11094759/)
123. [Lewis et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10592313/)
124. [Lialda prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/022000s030lbl.pdf)
125. [Lichtenstein et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31326606/)
126. [Long et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7216775/)
127. [NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/obefazimod)
128. [Ng et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38583900/)
129. [Olén et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31929014/)
130. [Olivera et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42838315/)
131. [Omvoh prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761279s005lbl.pdf)
132. [Pandey et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391273/)
133. [Park et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7534391/)
134. [Parra-Izquierdo et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42777529/)
135. [Porter et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7194476/)
136. [Remicade prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/103772s5412lbl.pdf)
137. [Rinvoq prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218347Orig1s008,211675Orig1s034lbl.pdf)
138. [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)
139. [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)
140. [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)
141. [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)
142. [Scherrer et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27999038/)
143. [Seidler et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.893/8433392)
144. [Shaffer et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8075066/)
145. [Shehab et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39182898/)
146. [Siegmund et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.1049/8433989)
147. [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12162142/)
148. [Skyrizi prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761105s053lbl.pdf)
149. [Steens et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5487684/)
150. [Stelara prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125261s173lbl.pdf)
151. [Streetwise Reports (2026)](https://www.streetwisereports.com/article/2026/07/01/clinical-stage-biotech-discloses-colitis-retreatment-results-gets-mixed-ratings.html)
152. [Tazi et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33387693/)
153. [Tilg et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.1109/8434071)
154. [Travis et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11144997/)
155. [Tremfya prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761061s034lbl.pdf)
156. [Tsai et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8934200/)
157. [Turner et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33359090/)
158. [Uceris prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203634s012lbl.pdf)
159. [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)
160. [UEG Week poster, Study 108 three-year analysis (2026)](https://www.abivax.com/wp-content/uploads/2026/10/Final-Poster-3.-Verstockt-OLE-3-yr-Dose-De-Esc.pdf)
161. [Vautrin et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6349857/)
162. [Velsipity prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/216956s002lbl.pdf)
163. [Vermeire et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33662385/)
164. [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/)
165. [Vermeire et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37129565/)
166. [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)
167. [WHO Drug Information (2021)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl125.pdf)
168. [Xeljanz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/203214s042lbl.pdf)
169. [Yang et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3865226/)
170. [Yarur et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/04/abivax-poster-elderly-yarur-ddw-2026.pdf)
171. [Zand et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7302133/)
172. [Zeposia prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209899s011s012lbl.pdf)
173. [Zhdanava et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10839463/)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
